<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704258</url>
  </required_header>
  <id_info>
    <org_study_id>#2020-01 (EU)</org_study_id>
    <nct_id>NCT04704258</nct_id>
  </id_info>
  <brief_title>Clinical Study of a Novel Transcatheter Anti-embolic Filter for Cerebral Protection During Aortic Valve Interventions</brief_title>
  <acronym>NAUTILUS</acronym>
  <official_title>Clinical Study of a Novel Transcatheter Anti-embolic Filter (TAF) for Cerebral Protection During Aortic Valve Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AorticLab Srl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AorticLab Srl</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to assess the safety, performance and treatment effect&#xD;
      of the use of AorticLab Transcatheter Antiembolic Filter (TAF), in preventing cerebral&#xD;
      thromboembolic complications in patients with indication for a TAVI (Transcatheter Aortic&#xD;
      Valve Implant).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single arm, prospective, multicenter non-randomized clinical study of the AorticLab TAF&#xD;
      System to prevent embolic complications during transcatheter aortic valve procedures. Forty&#xD;
      participants will be enrolled at up to six sites in Europe and will undergo clinical&#xD;
      follow-up at 24hrs ± 8hrs post-procedure, discharge or 7 days, whichever comes first and 30&#xD;
      days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TAF System Safety, rate of Major Adverse Cardiac and Cerebrovascular Events (MACCEs)</measure>
    <time_frame>7 days</time_frame>
    <description>related to TAF Device or Procedure as adjudicated by a Clinical Event Committee</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative occurrence of MACCEs</measure>
    <time_frame>30 days</time_frame>
    <description>MACCEs are defined by the Valve Academic Research Consortium (VARC-2) criteria.&#xD;
MACCEs include the following device-related safety outcomes:&#xD;
all-cause mortality including cardiovascular mortality;&#xD;
all stroke (disabling and non-disabling);&#xD;
bleeding (life-threatening or disabling);&#xD;
acute kidney injury (stage 2 or 3 including new dialysis);&#xD;
major device access related vascular complications;&#xD;
coronary artery obstruction requiring intervention;&#xD;
valve-related dysfunction requiring repeat procedure (balloon aortic valvuloplasty, repeat TAVI, or surgical aortic valve replacement)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>defined as successful placement, insertion and removal of the TAF System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Debris capture</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>by the TAF System with gross and histopathological evaluation including particle size and composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TAF System Usability</measure>
    <time_frame>immediately after procedure</time_frame>
    <description>graded by the Investigator with a 5-point Likert scale&#xD;
The minimum and the maximum values of the scale are defined as follows:&#xD;
(1) Unacceptable; (2) Poor; (3) Accetable; (4) Good; (5) Excellent</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Brain imaging (DW-MRI)</measure>
    <time_frame>within 2-5 days after procedure vs. baseline</time_frame>
    <description>Acute cerebral embolic burden reduction after TAVI, defined as number of new cerebral lesions in all cerebral territories assessed by DW-MRI</description>
  </other_outcome>
  <other_outcome>
    <measure>Brain imaging (DW-MRI)</measure>
    <time_frame>within 2-5 days after procedure vs. baseline</time_frame>
    <description>Acute cerebral embolic burden reduction after TAVI, defined as volume of new cerebral lesions in all cerebral territories assessed by DW-MRI</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurocognitive</measure>
    <time_frame>2-7 days and 30-days vs. baseline</time_frame>
    <description>Neurocognitive protection assessed by the National Institutes of Health Stroke scale (NIHSS):&#xD;
NIHSS will be used to assess participant's health related quality of life (higher scores mean a worse outcome)</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurocognitive</measure>
    <time_frame>discharge or 7 days and 30-days vs. baseline</time_frame>
    <description>Neurocognitive protection assessed by Montreal Cognitive Assessment (MoCA):&#xD;
MoCA Test allows people to quickly assess a patients cognitive health (higher scores mean a better outcome)</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurocognitive</measure>
    <time_frame>2-7 days and 30-days vs. baseline</time_frame>
    <description>Neurocognitive protection assessed by the modified Rankin Scale (mRS):&#xD;
mRS will be used to assess participant's health related quality of life (higher scores mean a worse outcome)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Intracranial Embolism and Thrombosis</condition>
  <arm_group>
    <arm_group_label>TAVI + Embolic protection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with severe native aortic valve stenosis who meet the clinically approved indications for aortic valve interventions such as TAVI</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAVI (Transcatheter Aortic Valve Implant)</intervention_name>
    <description>Placement of a filter to capture and remove emboli or debris detached during any transcatheter heart procedures</description>
    <arm_group_label>TAVI + Embolic protection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAF System</intervention_name>
    <description>Transcatheter Antiembolic Filter (TAF)</description>
    <arm_group_label>TAVI + Embolic protection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects of age ≥ 18 years&#xD;
&#xD;
          2. Subject is scheduled to undergo transfemoral aortic valve implant (TAVI) procedure on&#xD;
             a stenotic native aortic valve and is qualified based on pre-operative CT-scan&#xD;
             examination (trans-thoracic echocardiogram (TTE) can be used as confirmatory&#xD;
             assessment)&#xD;
&#xD;
          3. Subject anatomy with Ilio-femoral artery segment compatible with a 12 F device&#xD;
             catheter size&#xD;
&#xD;
          4. The subject and the treating physician agree that the subject will undergo the&#xD;
             scheduled pre-procedural testing and return for all required post-procedure follow-up&#xD;
             visits&#xD;
&#xD;
          5. The subject, or legally authorized representative, has been informed of the nature of&#xD;
             the study, agrees to its provisions and has provided written informed consent,&#xD;
             approved by the appropriate Medical Ethics Committee (EC) or Institutional Review&#xD;
             Board (IRB)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Clinical exclusion criteria (preoperative screening)&#xD;
&#xD;
          1. Subjects with hypercoagulable state that cannot be corrected by additional&#xD;
             periprocedural heparin&#xD;
&#xD;
          2. Subjects with contraindication to cerebral MRI&#xD;
&#xD;
          3. Subjects with a history of a stroke or transient ischemic attack within the prior 6&#xD;
             months&#xD;
&#xD;
          4. Subjects with known diagnosis of acute myocardial infarction (AMI) within 30 days&#xD;
             preceding the index procedure&#xD;
&#xD;
          5. Renal insufficiency (creatinine &gt; 3.0 mg/dL or Glomerular Filtration Rate GFR &lt; 30)&#xD;
             and/or renal replacement therapy at the time of screening&#xD;
&#xD;
          6. Subjects with a history of bleeding diathesis or coagulopathy or patients in whom&#xD;
             anti-platelet and/or anticoagulant therapy is contraindicated, patients who will&#xD;
             refuse transfusion, or patients with an active peptic ulcer or history of upper&#xD;
             gastrointestinal (GI) bleeding within the prior 3 months&#xD;
&#xD;
          7. Subjects with known hypersensitivity or contraindication to aspirin,&#xD;
             heparin/bivalirudin, clopidogrel/ticlopidine, nitinol, stainless steel alloy, and/or&#xD;
             contrast sensitivity that cannot be adequately pre-medicated&#xD;
&#xD;
          8. Subject is currently participating in another drug or device clinical study or has&#xD;
             other medical illnesses that may cause the subject to be non-compliant with the&#xD;
             protocol or confound the data interpretation&#xD;
&#xD;
          9. Subjects with a previously implanted prosthetic aortic valve (i.e., planned&#xD;
             valve-in-valve with a TAVI)&#xD;
&#xD;
         10. Subject requires an emergent procedure&#xD;
&#xD;
         11. Subject has active major psychiatric disease&#xD;
&#xD;
         12. Subjects with neurodegenerative or other progressive neurological disease or history&#xD;
             of significant head trauma followed by persistent neurologic defaults or known&#xD;
             structural brain abnormalities&#xD;
&#xD;
         13. Subject has an ejection fraction of 30% or less&#xD;
&#xD;
         14. Subjects with active endocarditis or other systemic infection&#xD;
&#xD;
         15. Subjects undergoing therapeutic thrombolysis&#xD;
&#xD;
         16. Subject is pregnant or lactating. Pregnancy confirmed by positive urine or serum test&#xD;
&#xD;
        Computerized Tomographic exclusion criteria (preoperative screening)&#xD;
&#xD;
          1. Subjects with documented friable or mobile atherosclerotic plaque in the aortic arch&#xD;
&#xD;
          2. Subjects with echocardiographic evidence of aortic mass, thrombus or vegetation&#xD;
&#xD;
          3. Subjects with a diameter of the ascending aorta &lt; 29 and &gt; 34 mm at baseline CT&#xD;
             (measured between 1 and 10 mm upstream the first vessel of the brachiocephalic trunk)&#xD;
&#xD;
          4. Subjects undergoing transcatheter aortic valve implantation (TAVI) via the&#xD;
             trans-axillary, trans-subclavian, or trans-aortic route&#xD;
&#xD;
          5. Subjects with severe peripheral arterial, abdominal aortic, or thoracic aortic disease&#xD;
             that precludes delivery sheath vascular access&#xD;
&#xD;
          6. Subjects in whom the aortic arch is heavily calcified, severely atheromatous, or&#xD;
             severely tortuous&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco Osta</last_name>
    <role>Study Chair</role>
    <affiliation>AorticLab Srl</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enrico Pasquino</last_name>
    <phone>+41795388214</phone>
    <email>enrico.pasquino@aorticlab.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>CUB Hôpital Erasme (ULB)</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Elvin Kedhi</last_name>
      <email>ekedhi@me.com</email>
    </contact>
    <investigator>
      <last_name>Elvin Kedhi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa di Cura Policlinico di Monza</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Filippo Scalise</last_name>
      <email>filippo.scalise@policlinicodimonza.it</email>
    </contact>
    <investigator>
      <last_name>Filippo Scalise</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Matteo Montorfano</last_name>
      <email>montorfano.matteo@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Matteo Montorfano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>MI</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Federico De Marco</last_name>
      <email>Federico.DeMarco@grupposandonato.it</email>
    </contact>
    <investigator>
      <last_name>Federico De Marco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>Transcatheter Anti-embolic Filter</keyword>
  <keyword>Cerebral Embolic Protection</keyword>
  <keyword>Embolic Protection Device</keyword>
  <keyword>Debris</keyword>
  <keyword>Embolic material</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Embolism</mesh_term>
    <mesh_term>Intracranial Embolism and Thrombosis</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Embolism and Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

